Video Experimental Relacionado

Updated: Jan 15, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Función de MECOM Crítica para el Cáncer de Próstata Resistente al Tratamiento Impulsado por AR

Surendra Gulla¹, Tej Sharma¹, Ephraim Gardner¹

¹University at Buffalo, State University of New York Buffalo, New York United States.

Cancer research

|January 13, 2026

Resumen

MECOM/EVI1 impulsa la progresión del cáncer de próstata al coactivar la señalización no canónica del receptor de andrógenos. La sobreexpresión de MECOM predice la sensibilidad a inhibidores de PARP, ampliando las opciones de tratamiento para el cáncer de próstata resistente a la castración.

Sus antecedentes:

La progresión del cáncer de próstata implica la reprogramación del cistroma del receptor de andrógenos (AR).
El cáncer de próstata resistente a la castración (CRPC) a menudo utiliza la señalización no canónica de AR resistente a los inhibidores de la señalización de AR (ARSI).

Conclusiones:

EVI1 juega un papel crítico en la supervivencia celular dentro del panorama de la cromatina reprogramada por AR del cáncer de próstata.
La sobreexpresión de MECOM es un biomarcador potencial para ampliar el uso de inhibidores de PARP más allá de los cánceres con mutación HRR.

Palabras clave:

cáncer de próstata cáncer de próstata resistente a la castración receptor de andrógenos MECOM EVI1 inhibidores de PARP señalización no canónica super-enhancers

Más Videos Relacionados

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Videos de Conceptos Relacionados

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...